Invited Speaker
- Presidential Symposium / Plenary Session
- Scientific Session
- Joint Symposium
- Education Session
- Nursing Session
- Student/Resident Lecture
- Case Discussion
- Industry Symposium
Presidential Symposium
-
PS
Making Sense of CAR-T Cell Therapy for Lymphoma
David G Maloney
Fred Hutchinson Cancer Research Center, USA
CV
Abstract
Plenary Session
-
PL01
NGS-based MRD Monitoring Pre- and Post-allogeneic HSCT for AML
Michael Heuser
MHH Hospital, Germany
CV
Abstract
-
PL01
Conditioning Intensity of Allogeneic Transplantation for AML with MRD
Christopher S. Hourigan
NIH, USA
CV
Abstract
-
PL02
Engineering and Design for Next Generation CAR-T Cells
Sham Mailankody
MSKCC, USA
CV
Abstract
-
PL03
Development and Application of Machine Learning in Hematopoietic Stem Cell Transplantation
Yasuyuki Arai
Kyoto University, Japan
CV
Abstract
-
PL03
Current Statistical Issues in Hematopoietic Cell Transplantation
Haesook T. Kim
Dana-Farber Cancer Institute, USA
CV
Abstract
Scientific Session
-
SS01
High Throughput Single Cell Analysis in AML
Koichi Takahashi
MDACC, USA
CV
Abstract
-
SS01
Therapeutic Implications of Genomic Profiling in Acute Myeloid Leukemia
Omar Abdel-Wahab
MSKCC, USA
CV
Abstract
-
SS01
Clonal Hematopiesis of Indeterminate Potential in Transplantation
Kyoung Ha Kim
Soonchunhyang University Hospital, Korea
CV
Abstract
-
SS02
FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML
Richard T. Maziarz
Oregon Health and Science University, USA
CV
Abstract
-
SS02
Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS
Tapan Kadia
MDACC, USA
CV
Abstract
-
SS02
Treatment Strategies after Allogeneic HSCT in Relapsed ALL
Ik-Chan Song
Chungnam National University College of Medicine, Korea
CV
Abstract
-
SS03
Current Ultimate Choice for Conditioning Regimens
Christina Peters
St. Anna Children’s Hospital, Austria
CV
Abstract
-
SS03
HSCT Incorporation with Non-Traditional Agents: Clofarabine, Treosulfan
Franca Fagioli
The University of Turin, Italy
CV
Abstract
-
SS03
Treatment after Failure of CD-19 Directed Therapy
Nirali N. Shah
National Cancer Institute, USA
CV
Abstract
-
SS04
Mass Spectrometry for Detection of Minimal Residual Disease in Multiple Myeloma
Noemi Puig
University Hospital of Salamanca, Spain
CV
Abstract
-
SS04
Role of Tandem Autologous Stem Cell Transplant in High-Risk Patients with Multiple Myeloma
Hyeon-Seok Eom
National Cancer Center, Korea
CV
Abstract
-
SS04
CAR T in Relapsed/Refractory MM” Versus “CAR T in High Risk
Nina Shah
The University of California San Francisco, USA
CV
Abstract
-
SS05
Treosulfan Based Conditioning for Nonmalignant Diseases
Ho Joon Im
University of Ulsan College of Medicine, Korea
CV
Abstract
-
SS05
Haematopoietic Stem Cell Transplantation and Gene Therapy for Immunodeficiency
Andrew Gennery
Newcastle University, UK
CV
Abstract
-
SS05
Optimizing the Conditioning Regimen of HSCT for Acquired Bone Marrow Failure in Children
Nao Yoshida
Japanese Red Cross Nagoya First Hospital, Japan
CV
Abstract
-
SS05
Bridge to Transplantation for Refractory HLH
Michael B Jordan
Cincinnati Children's Hospital Medical Center, USA
CV
Abstract
-
SS06
Ibrutinib and Other B Cell Directed Therapy in Chronic GVHD
Corey Cutler
Dana-Farber Cancer Institute, USA
CV
Abstract
-
SS06
Ruxolitinib for GVHD Management
Robert Zeiser
University Medical Center Freiburg, Germany
CV
Abstract
-
SS06
Intestinal Goblet Cell and IL-25 in Intestinal GVHD
Takanori Teshima
Hokkaido University Graduate School of Medicine, Japan
CV
Abstract
-
SS07
CAR-NK Cells: A Promising Cellular Immunotherapy for Hematologic Malignancies
Jianhua Yu
City of Hope National Medical Center, USA
CV
Abstract
-
SS07
Adoptive T-Cell Immunotherapy- Experiences in Preclinical and Clinical Studies
Tai-Gyu Kim
The Catholic University of Korea, Korea
CV
Abstract
-
SS07
Novel Immunotherapeutic Approaches with Antibody Drugs
Hermann Einsele
University Hospital Würzburg, Germany
CV
Abstract
-
SS08
Haploidentical Transplantation with PTCy for SAA
Régis Peffault de Latour
Saint-Louis Hospital, France
CV
Abstract
-
SS08
Haploidentical Transplantation with ATG for SAA
Sung-Eun Lee
The Catholic University of Korea,Korea
CV
Abstract
-
SS08
Immunosuppressive Therapy Versus Haploidentical Transplantation in Adults with SAA
Xiao jun Huang
Peking University Institute of Hematology, China
CV
Abstract
-
SS09
'Off the shelf' CAR-T Cells for Relapsed Refractory Lymphoma and MM
Sattva S Neelapu
The University of Texas M.D. Anderson Cancer Center, USA
CV
Abstract
-
SS09
Use of CAR -T Cells in Allogeneic Stem Cell Transplantation
Peihua Lu
Lu Daopei hospital, China
CV
Abstract
-
SS09
Real World Experience of CAR-T Cells in Korea
Won Seog Kim
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
-
SS10
Autologous Stem Cell Transplantation for Aggressive B-cell Lymphomas in the Frontline Setting: Current Controversies and Advances
Narendranath Epperla
The Ohio State University Comprehensive Cancer Center, USA
CV
Abstract
-
SS10
High Dose Therapy and Autologous Stem Cell Transplantation in Patients with Indolent Lymphoma
Julie M. Vose
University of Nebraska Medical Center, USA
CV
Abstract
-
SS10
The Role of Allogeneic Stem Cell Transplantation for Relapsed and Refractory Lymphoma in the Era of CAR-T Cell Therapy
Youngwoo Jeon
The Catholic University of Korea, Korea
CV
Abstract
-
SS11
Comparison of Allogeneic Stem Cell Transplantation from Matched Unrelated Donor (URD) and Haploidentical Family Donor (HFD) in Adults with Hematological Malignancies Focusing on Acute Leukemia
Arnon Nagler
Tel Aviv University, Israel
CV
Abstract
-
SS11
Cord Blood Versus Haploidentical Stem Cell Transplantation for Hematological Malignancies
Jae-Ho Yoon
The Catholic University of Korea, Korea
CV
Abstract
-
SS11
Unrelated Donor vs Haploidentical αβ T-cell- and B-cell-depleted HSCT in Children with Acute Leukemia
Alice Bertaina
Stanford School of Medicine, USA
CV
Abstract
-
SS12
Prophylactic/preemptive DLI: Real World Experience
Xiao jun Huang
Peking University Institute of Hematology, China
CV
Abstract
-
SS12
Therapeutic DLI in Relapsed/Refractory Hematologic Malignancy
Bhagirathbhai Dholaria
Vanderbilt University Medical Center , USA
CV
Abstract
-
SS12
Post-transplantation Cyclophosphamide based Haploidentical Transplantation and Donor Lymphocyte Infusion
Hyoung Jin Kang
Seoul National University College of Medicine, Korea
CV
Abstract
-
SS13
Error-corrected Next Generation Sequencing to Detect MRD in AML
Nikhil Patkar
Tata Memorial Centre, India
CV
Abstract
-
SS13
Haploidentical CD19 CAR-T Cell for Treatment of Relapsed Refractory ALL
Suradej Hongeng
Mahidol University, Thailand
CV
Abstract
-
SS13
Hematopoietic Stem Cell Transplantation Have Relation with Clinical Phenotype of Fanconi Anemia Patients: Iranian Experience
Amir Ali Hamidieh
Tehran University of Medical Sciences, Iran
CV
Abstract
Joint Symposium
-
JS01
Infectious Complication: CMV Infection
Yae-Jean Kim
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
-
JS01
Human Herpesvirus 6B Encephalitis after Allogeneic Stem Cell Transplantation: Diagnostic and Treatment Strategies in Japan
Masao Ogata
Oita University, Japan
CV
Abstract
-
JS01
Gut GVHD-microbiome
Dong-Mi Shin
Seoul National University College of Medicine, Korea
CV
Abstract
-
JS01
Intestinal Dysbiosis and GVHD; Preclinical and Clinical Findings
Daigo Hashimoto
Hokkaido University, Korea
CV
Abstract
-
JS02
Bridging Therapy To Allo-HSCT (Novel Agent before and after Allo-HSCT)
Ali Bazarbachi
American University of Beirut, Lebanon
CV
Abstract
-
JS02
Novel Agents for Relapsed or Refractory Hodgkin Lymphoma in Korea
Won Seog Kim
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
-
JS02
PTCy in Haplo-HSCT in HL
Anna Sureda
Institut Català d'Oncologia, Spain
CV
Abstract
-
JS02
Allo-HSCT in Hodgkin Lymphoma in Korea
Seok-Goo Cho
The Catholic University of Korea, Korea
CV
Abstract
-
JS03
The Role of Flow-, PCR- and NGS-based MRD in guiding HCT and CAR T-cell therapy for Acute Lymphoblastic Leukemia
Michael Pulsipher
Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, USA
CV
Abstract
-
JS03
NGS-based MRD Before and After Allogeneic HCT in Myeloid Neoplasms
Myungshin Kim
The Catholic University of Korea, Korea
CV
Abstract
-
JS03
Molecular Measurable Residual Disease for AML Patients Who Undergoing HSCT
Byung Sik Cho
The Catholic University of Korea, Korea
CV
Abstract
-
JS04
CAR-T Cell Therapy on Pancreatic Cancer
John Rasko
Royal Prince Alfred Hospital, Australia
CV
Abstract
-
JS04
Strategies of CAR-T Cell Therapy to Overcome Challenges in Solid Tumors
Baeckseung Lee
MJCELLBIO, Korea
CV
Abstract
-
JS04
Development of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells against Malignant Glioma
Song-Jae Lee
CellabMED Inc., Korea
CV
Abstract
-
JS05
Second Malignancies after Allo-HSCT & Auto-HSCT in Turkey
Huseyin Saffet Bekoz
Medipol University Hospital, Turkey
CV
Abstract
-
JS05
Secondary Maligancy Following Allogeneic Stem Cell Transplantaiton in Adult Patients
Seung-Hwan Shin
The Catholic University of Korea, Korea
CV
Abstract
Education Sessionm
-
ES01
VOD/SOS: Prophylactic, Preemptive and Curative Treatment
Paul Richardson
Dana-Farber Cancer Institute, USA
CV
Abstract
-
ES01
Transplantation-associated TMA: Pathophysiology, Risk Factors and Management
Christopher Dandoy
Cincinnati Children’s Hospital Medical Center , USA
CV
Abstract
-
ES01
Management of Hemorrhagic Cystitis
Ja Min Byun
Seoul National University College of Medicine, Korea
CV
Abstract
-
ES02
Nutritional Management in Patients Treated with Stem Cell Transplantation
Ka-Won Kang
Korea University College of Medicine, Korea
CV
Abstract
-
ES02
Management of Long-Term Endocrine Complications after Hematopoietic Stem Cell Transplantation
Jin-Ho Choi
University of Ulsan College of Medicine, Korea
CV
Abstract
-
ES02
Fertility Preservation and Reproductive Health in Allogeneic Hematopoietic Stem Cell Transplantation
Seungmin Hahn
Yonsei University College of Medicine, Korea
CV
Abstract
-
ES03
The Role of Stem Cell Transplantation for WM
Masatoshi Sakurai
Keio University, Japan
CV
Abstract
-
ES03
HSCT in Patients with Blastic Plasmacytic Dendritic Cell Neoplasm
Ji Hyun Lee
Dong-A University, Korea
CV
Abstract
-
ES03
Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis. For Whom, When and How?
Chul Won Jung
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
-
ES04
Germline Predisposition: an Emerging Issue in Donor Selection for HSCT
Lucy Godley
The University of Chicago, USA
CV
Abstract
-
ES04
Chimerism Monitoring Using NGS Assay
Hyun-Ji Lee
Pusan National University Yangsan Hospital, Korea
CV
Abstract
-
ES04
NGS-based HLA Typing
Yun Ji Hong
Seoul National University College of Medicine, Korea
CV
Abstract
-
ES05
Statistical Methods in HSCT
Hwa Jung Kim
Ulsan University College of Medicine, Korea
CV
Abstract
-
ES05
Designing Clinical Studies in the HSCT Setting
Seokyung Hahn
Seoul National University College of Medicine, Korea
CV
Abstract
Nursing Session
-
NS01
Current Status of Blood and Marrow Transplantation in Korea
Hye youn Lee
Seoul National University College of Medicine, Korea
CV
Abstract
-
NS01
The Role of Coordinator Nurses in Field of Hematopoietic Stem Cell Transplantation
Minjin Choi
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
-
NS02
Updated View on the Treatment of Hemato-Oncology
Ja Min Byun
Seoul National University College of Medicine, Korea
CV
Abstract
-
NS02
Introduction of CAR-T Therapy
Sang Eun Yoon
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
Student/Resident Lecture
-
RL01
Current Progress in Cellular Immunotherapy for Hematologic Malignancies
Sung-Hoon Jung
Chonnam National University Hwasun Hospital, Korea
CV
Abstract
-
RL01
Understanding the Role of Genetics in Hematologic Malignanci
Saeam Shin
Yonsei University, Korea
CV
Abstract
-
RL01
Long-term Management in Pediatric Patients after HSCT
Eu Jeen Yang
Pusan National University School of Medicine, Korea
CV
Abstract
Case Discussion
-
CD01
Primary CNS Lymphoma
Yoon Seok Choi
Ajou University School of Medicine, Korea
CV
Abstract
-
CD02
Ex Vivo T-cell Depletion vs. PTCy for Upfront Haploidentical Transplantation in Pediatric Very Severe Aplastic Anemia: Ex Vivo TCD Side
Sung Han Kang
University of Ulsan College of Medicine, Korea
CV
Abstract
-
CD02
Ex Vivo T-cell Depletion vs. PTCy for Upfront Haploidentical Transplantation in Pediatric Very Severe Aplastic Anemia: PTCy side
Kyung Taek Hong
Seoul National University College of Medicine, Korea
CV
Abstract
Industry Symposium
-
IS01
Mastering the Evolution in Therapy-Related Acute Myeloid Leukemia & Acute Myeloid Leukemia with Myelodysplasia-Related Change
Hawk Kim
Gachon University College of Medicine, Korea
CV
Abstract
-
IS02
Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Thomas Martin
University of California San Francisco, USA
CV
Abstract
-
IS03
Elevating the CML Treatment Goals by Personalizing Treatment with Dasatinib
Jeff Lipton
University of Toronto, Canada
CV
Abstract
-
IS04
KYMRIAH: Rewriting Cancer Survival in DLBCL
Michael Dickinson
Peter MacCallum Cancer Cantre, Australia
CV
Abstract
-
IS05
Optimal Treatment Strategy for FLT3 Mutated AML
Andrew Wei
Monash University, Australia
CV
Abstract
-
IS06
CMV Prophylaxis for Allogeneic HSCT Patients
Youngil Koh
Seoul National University College of Medicine, Korea
CV
Abstract
-
IS07
Updated Treatment Strategy of Immune Thrombocytopenia with TPO Receptor Agonist
Jun Ho Jang
Sungkyunkwan University School of Medicine, Korea
CV
Abstract
-
IS08
CAR T-Cell Therapies for Multiple Myeloma: Where are We Now and What are the Key Issues?
Thomas Martin
University of California San Francisco, USA
CV
Abstract
-
IS09
Current Strategy for MRD Positive and Relapse ALL
Itaru Kato
Kyoto University Hospital, Japan
CV
Abstract